Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arrhythmia worries lead to revised labeling for Zofran

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline's antiemetic Zofran (ondansetron) and its generic equivalents – drugs used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy and surgery – are no longer being recommended for use at the 32mg single intravenous dose after preliminary study results showed that dose may lead to QT interval prolongation, an abnormal electrical activity of the heart, which can result in a potentially fatal arrhythmia, known as torsades de point (TDP).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC017968

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel